Post-PCI Phase (Patient in AFib): Long-term Prevention of Bleeding
We Recommend
Disclosures
Within the last 24 months, I have financial relationship(s) or affiliation(s) with a manufacturer, marketer, reseller, or distributor of a healthcare product or service involved in the management of patients with any cardiovascular disease to include devices, drugs, and digital health care products listed below:
- Consultant Fee/Honoraria/Speaker's Bureau (Personal) - Angel Medical; Bayer AG; Bristol-Myers Squibb; Amarin; Amgen; Boehringer Ingelheim; Boston Clinical Research Institute; Boston Scientific Corporation; Caladrius Biosciences; CRF; CeleCor Therapeutics; CSL Behring; Chiesi; DCRI; Eli Lilly and Company; GE Healthcare; Gilead; Impact Bio; Janssen; Johnson and Johnson; The Medicine's Company; Medtelligence; Merck & Co.; Microport; Novo Nordisk; PERT Consortium; Pharma Mar; Portola; Thrombolytic Science; Sanofi-Aventis; Somahlution; Vereseon; WebMD; Amag Pharmacuticals; Eidos Therapeutics; Kiniksa Pharmaceuticals; Micodrop, LLC
- Grant Support/Research Contract (Institutional) - CSL Behring; SCAD Alliance
- Grant Support/Research Contract (Both) - Janssen; Johnson & Johnson
- Consultant Fee/Honoraria/Speaker's Bureau (Institutional) - MedImmune
- Equity/Stock(s)/Options (Personal) - nference
- Royalty/Intellectual Property Rights (Personal) - UpToDate